Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How about some Jon Doe suits brought by unidentified shareholders against H for failure to deliver? 1 share enough?
Welland, not Wellington. This IPad guesses what I want to say.
Very timely, DMC8, in light of lead article in IBD weekly issue about what MRK, AZN and many others are doing in this area that I just finished reading while traversing the Wellington canals between Toronto and Niagara Falls and Lake Erie.
More AMRN, part of the story anyway.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174707300
Thanks for that link to a MDWD rumor(?). We hold shares of 3M, SOLV, as well as ~ 15k shares of VCEL….I could be wrong, but doesn’t VCEL have some exclusive rights to MDWD burn therapy IP at least in the U.S.?
AMRN, our #1 pick, is now a meme stock featured by “Roaring Kitty” at the Reddit site. More from me later, time permitting. A link is available from the IHub AMRN board. A number of old and new AMRN shareholders have replied to “Roaring Kitty.” AMRN appears to have closed at $0.70.
INSM website contains “Phase 3 Data Presentation at the 7th World Bronchiectasis Conference” dated July 4, 2024. The presentation may be downloaded in slide form.
The additional data presentation likely accounts for the share price increase at 4 pm close = $70, + 12.9%.
Question: will this same mechanism affect BRAVE Vascepa trial results for Alzheimer’s, dementia, also in a positive sense?
Ziploc, did you see NVO price action premarket in light of Mass Eye data on potential blindness from Ozempic, Wegovy interrupting blood flow to optic nerve? Something else for FDA to investigate with respect to those 2 weight loss drugs?
Roche reported today that its Phase 2-3 Skyscraper-06 trial of Tiragolumab + Tecentriq + chemotherapy failed to meet the primary endpoints, OS and PFS, in NSCLC.
Further, the Tecentriq arm actually reduced OS and PFS when assessed against the comparator arm of pembrolizumab + chemotherapy in the intent to treat population.
The trial will be halted.
Had not seen that interview, Jasbg. I appreciate the link.
Post # 252470 by jbog starts the discussion, other # is incorrect.
Anyone here being prescribed NVO’s weight loss drugs Ozempic or Wegovy should look at discussion of links to a Mass Eye JAMA paper published yesterday, beginning with a jbog post ‘271 on the Biotech Value message board. Risk of blindness from an interruption of blood flow to an optic nerve is the issue.
ANVS near double in share price @ ~ $10/share on news of effectiveness of its Parkinson’s drug, buntanetap, met pre-specified primary and secondary endpoints. The treatment halted cognitive decline in all enrolled patients. Shares now + ~ $9.48.
sleven, I am not 100% sure of what Hikma will do. H is skating on thin ice. “No comment” for now.
OPTT is now trading ~ $0.45-0.52/share. We have 10k shares in each of 2 real Schwab accounts, and had it on our list of potential contest picks……sigh. Congrats to NSOMNIYAK.
One of our picks, CDMO, has an earnings call AH today. We will see what happens there. CDMO is furnishing bulk material to HALO from which it fashions subcutaneous delivery products useful to a number of companies(e.g., JNJ) that obviate much slower vein delivery. CDMO has recently expanded its reactor capacity to make biological molecules like monoclonal antibodies in single use reactors. Rumors abound that CDMO is a M/A candidate and will be bought within the next year.
More on CDMO and also AMRN, our #1 pick, later.
A petition to the Commissioner of FDA to enforce the previous evidence-based scientific decision of FDA that Lovaza has no therapeutic efficacy/use in treatment of CVD and that FDA has not approved Lovaza for that indication might be interesting for Amarin to pursue, in light of remarks in recent CAFC opinion re Hikma’s drug.
FDA has approved ANIP’s generic version of Naproxen, per a PR today.
Interesting…..any idea how soon ANIP will market that generic?
President Biden’s remarks re LLY’s and NVO’s weight loss drug prices, coupled with the USA editorial, could have a positive effect on Amarin share price…..wait and see, I guess. CNBC interview of Powell and Lagarde this morning……..?
Anybody read the red-line copy of Dr. Reddy’s antitrust amended complaint in N.J.? Thanks for link, sleven.
The appearance of that Squire-authored article is timely, but it suffers from some major inaccuracies.
Amarin did not lose its patents covering Vascepa and its various indications. Squire apparently is unaware of Amarin’s Delaware infringement suit against Hikma that is currently ongoing, nor does he mention this past week’s CAFC opinion related to that suit in which claims of those patents are quoted.
Has anybody seen a sign of Zero-Dated Options being used by short sellers, day traders or market makers to “control” ANIP share price? See the 7/01/2024 Barron’s La Monica article at pages 18-19. Bets on market moves. Wide spreads between Bid and Ask prices at various times of day. Sharp intraday moves ahead of earnings reports. Major exchanges have not approved them yet for individual stocks, but who knows what goes on at the numerous minor exchanges that are appearing. OCC is the gatekeeper, with SEC as the regulator.
Zero days to expiration = 0DTE. Cboe uses them. Some foreign exchanges also.
Correct, if I discern correctly what you mean by “that”.
From page 5, middle paragraph of the CAFC opinion:
“…..Although Hikma’s original proposed label included the CV Limitation of Use, Hikma later amended the label to remove that limitation around the same time it submitted its section viii statement carving out the uses covered by the asserted patents.”
The Fed. Cir. opinion, page 9, has this helpful note taken from Amarin’s brief; the note’s last phrase should be generally true for all generics:
“….[the] product label evidence(s) Hikma’s specific intent to actively encourage physicians to directly infringe the asserted patents by prescribing its generic icosapent ethyl product for the off-label CV indication, an indication for which Hikma did not get FDA approval….”
The Court also noted, page 7, that the FDA’s “AB” rating for a generic drug when used as labeled “does not reflect a decision of therapeutic equivalence for off-label use” for a a different CV indication.
That said, there should be no generic like Hikma in business selling its generic IPE composition in competition with Amarin’s branded and patented Vascepa for use in any of the Reduce-It CVD indications.
TRO? P.I.?
Per a Schwab link, earnings expected after hours on 7/01/2024.
I thought you had already read the Hazel-Atlas case decided in the 1940s. What you describe in your question happened there, many years after the fraud occurred and the patents were held invalid.
Marjac, see in that regard 35 U.S.C. 271(e)(4) subparagraph (A).
As a start, you might consider the Supreme Court opinion in the 2016 Halo Electronics case, 136 S.Ct. 1923, and its discussion of 35 U.S.C. 284. See also 35 U.S.C. 271(e)(4), paragraphs (A),(B) and (C) and 35 U.S.C 298. Damages are an aspect of patent law I have never focused on.
Sleven, TC11: Having worked at the CCPA for 10 years, having argued Government positions before the CCPA and CAFC for another 10 years, I believe there are multitudes of cases in the entire Federal judiciary that apply established, settled law to different sets of facts. Those cases are also precedents.
I do recall one case that I argued before the CCPA where there was no established case law that could be cited to support either the government position or the GE(appellant) position. The patentability of new, useful life forms as “manufactures” or “compositions of matter”(35 U.S.C.101) (other than plants or plant varieties) was ultimately decided in a 5 Justice opinion by the Supreme Court, 4 Justices dissenting. That was the Chakrabarty case, decided in June 1980.
No law “changed,” #sleven. Careful reading of the opinion confirms that established law was applied to the present “plausible” or admitted facts alleged in the complaint. The case did not arise in the context of a trial already held before a jury with “plausible” facts actually found to be facts, or a case arising from grant of a preliminary injunction.
How well does the generic work for you; have you been taking the generic long enough to get worthwhile comparative results? What company’s name is on the bottle label, and what “brand” name does that company use to distinguish it from the Amarin brand Vascepa? Are you experiencing side effects like others here do, and like peer-reviewed literature describes?
Will ALNY’s MAB be in HALO’s client med portfolio? See the interview of CNBC-TV contributor at 8:00 a.m. this morning. The MAB(costly now) cuts death risk on treatment of CVD event by ~ 30%.
ALNY MAB cuts risk of death and risk of other CVD event treatment indications by ~ 30%, per CNBC-TV contributor interviewed this morning.
OT: ALNY MAB med(costly now) cuts risk of death and other CVD indications by ~ 30%, per CNBC-TV contributor who was interviewed 8:00 a.m. today.
Bloomberg does report other news of potential importance to Amarin this morning: A heart surgeon( also a former mayor of Tehran) is in contention to become new President of Iran, in an election to replace the former President killed in a helicopter crash that was reported weeks ago. See Bloomberg’s “Quick Take” for further discussion.
Amarin has already shipped inventory quantities of Vascepa to the Middle East.
Does that Iran heart surgeon know the head of FDA or the CEO of NVS, both cardiologists?
The above election, plus elections in France(called by Macron) and U.K., will be held by July 4.
Odd/Perhaps amusing to some persons that 3 Bloomberg analysts do not pick a single Biotech company as a M/A candidate despite all that cash firepower extant on BP and other companies balance sheets!! Remember the interview(s) of John Thero by other Bloomberg analysts 4-5 years ago.
Why does Amarin partner Mochida appear to be absent from that company market report?
What makes you think there is such a generic med called Vascepa or Vazkepa?
Doesn’t Amarin have international trademark registrations for Vascepa and Vazkepa?
Rmb, cbb: Not enough people appear to have read the OIST article from Japan re reversal of Alzheimer’s Disease and the remarkable slowing of cognitive decline in mice.
My question out of near total ignorance of terminology: Are the molecules/enzymes referred to in OIST article working in a manner similar or identical to the manner in which Vascepa interacts with the lipoproteins that Bhatt and Mason talked about in presentations at the ACC Scientific Session in April 2024? Or is a totally different MOA involved?
Did you see any oil exploration companies in djohn’s list of pharmaceutical companies, like MRK?